Brief: Theravance Biopharma Announces Approval Of Yupelri By China's NMPA
26/06/2025 11:03
June 26 (Reuters) - Theravance Biopharma Inc TBPH.O: THERAVANCE BIOPHARMA ANNOUNCES APPROVAL OF YUPELRI® (REVEFENACIN) BY CHINA'S NMPA THERAVANCE BIOPHARMA INC - APPROVAL TRIGGERS $7.5 MILLION MILESTONE PAYMENT FROM VIATRIS Source text: ID:nPn4vc42Wa Further company coverage: TBPH.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Theravance Biopharma
See all newsIreland's Theravance Biopharma Q1 revenue beats estimates on YUPELRI growth
Ireland's Theravance Biopharma Q4 revenue misses expectations
Corrected: BRIEF-Theravance Biopharma Q4 Operating Income USD 20.012 Million
U.S. STOCKS ON THE MOVE-Versant Media Group, Lithium miners, Expedia Group
U.S. STOCKS ON THE MOVE-Expedia Group, Blue Owl Capital, Enphase Energy